Cardiovascular disease and COVID-19, a deadly combination: A review about direct and indirect impact of a pandemic

Vidal-Pérez, Rafael; Brandão, Mariana; Pazderník, Michal; Kresoja, Karl‐Patrik; Carpenito, Myriam; Maeda, Shin; Casado‐Arroyo, Ruben; Muscoli, Saverio; Pöss, Janine; Fontes‐Carvalho, Ricardo; Vázquez‐Rodríguez, José Manuel

doi:10.12998/wjcc.v10.i27.9556

Cited by 18 publications

(10 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The same behavior is seen for the mortality rate due to CVD ( Figure 5 ). The pandemic’s indirect impact on the management of cardiovascular disease could partially be responsible for the higher-than-expected mortality toll associated with COVID-19 [ 30 ]. The total mortality rate by county is presented in Figure 5 a.…”

Section: Resultsmentioning

confidence: 99%

Toxicity Risk Assessment Due to Particulate Matter Pollution from Regional Health Data: Case Study from Central Romania

Maftei,

Vaseashta,

Poinareanu

2024

Toxics

View full text Add to dashboard Cite

Air pollution poses one of the greatest dangers to public well-being. This article outlines a study conducted in the Central Romania Region regarding the health risks associated with particulate matter (PM) of two sizes, viz., PM10 and PM2.5. The methodology used consists of the following: (i) an analysis of the effects of PM pollutants, (ii) an analysis of total mortality and cardiovascular-related mortality, and (iii) a general health risk assessment. The Central Region of Romania is situated in the Carpathian Mountains’ inner arch (consisting of six counties). The total population of the region under investigation is about 2.6 million inhabitants. Health risk assessment is calculated based on the relative risk (RR) formula. During the study period, our simulations show that reducing these pollutants’ concentrations below the new WHO guidelines (2021) will prevent over 172 total fatalities in Brasov alone, as an example. Furthermore, the potential benefit of reducing annual PM2.5 levels on total cardiovascular mortality is around 188 persons in Brasov. Although health benefits may also depend upon other physiological parameters, all general health indicators point towards a significant improvement in overall health by a general reduction in particulate matter, as is shown by the toxicity assessment of the particulate matter in the region of interest. The modality can be applied to other locations for similar studies.

show abstract

Section: Resultsmentioning

confidence: 99%

Toxicity Risk Assessment Due to Particulate Matter Pollution from Regional Health Data: Case Study from Central Romania

Maftei,

Vaseashta,

Poinareanu

2024

Toxics

View full text Add to dashboard Cite

show abstract

“…Therefore, patients with CVD should not stop taking these drugs for secondary prevention. In patients with COVID-19, statin therapy has been reported to be more likely to be complicated by side effects such as hepatic cytolysis or even severe rhabdomyolysis, and therefore it may be appropriate to temporarily suspend statin therapy during the acute infection [70]. Despite the understanding of the key role of endothelial dysfunction in the early stages of both diseases compared here, radical endothelial-related treatments have not been proposed for either COVID-19 or atherosclerosis [62].…”

Section: Mechanismsmentioning

confidence: 92%

“…The observed increase in pre-hospital mortality and out-of-hospital cardiac arrests indicates the negative impact of the pandemic on overall mortality rates from acute myocardial infarction, associated with a decrease in the availability of qualified inpatient cardiac care for somatic patients in COVID-19 pandemic. In other words, one disease interfered with the control of another not only at the pathophysiological, but also at the medical and social level [70].…”

Section: Mechanismsmentioning

confidence: 99%

Aterosclerosis, Cardiovascular Disorders And Covid-19: Comorbid Pathogenesis

Makarova¹,

Ryabkova²,

Салухов³

et al. 2022

Preprint

View full text Add to dashboard Cite

The article describes how atherosclerosis and coronavirus disease 19 (COVID-19) may affect each other. The features of this comorbid pathogenesis at various levels (vascular, cellular and molecular) are considered. A bidirectional influence of these conditions is described: the presence of cardiovascular diseases affects different individual susceptibility to viral infection. In turn, SARS-CoV-2 can have a negative effect on the endothelium and cardiomyocytes, causing blood clotting, secretion of pro-inflammatory cytokines, and thus exacerbating the development of atherosclerosis. In addition to the established entry into cells via ACE2 принимая во внимание его влияние на, other mechanisms of SARS-CoV-2 entry are currently under investigation, for example, through CD147. Pathogenesis of comorbidity can be determined by the influence of the virus on various links which are meaningful for atherogenesis: generation of oxidized forms of LDL, launch of a cytokine storm, damage to the endothelial glycocalyx, and mitochondrial injury. The transformation of a stable plaque into an unstable one plays an important role in the pathogenesis of atherosclerosis complications and can be triggered by COVID-19. The impact of SARS-CoV-2 on large vessels such as aorta is more complex than previously thought considering its impact on vasa vasorum. Current information on the mutual influence of the medicines used in the treatment of atherosclerosis and acute COVID-19 is briefly summarized

show abstract

“…The global outbreak of COVID-19, caused by the novel coronavirus, SARS-CoV-2, resulted in a pandemic that disrupted healthcare, especially among vulnerable populations 1 2. COVID-19 infection may worsen vascular diseases by disrupting the coagulation cascade and exacerbating inflammatory responses 3 4. Although prior studies have shown that COVID-19 increases the risk of poor outcomes among patients with ischaemic stroke,5 6 there is a paucity of studies based on nationally representative data evaluating the potential impact of the COVID-19 pandemic on the trends in haemorrhagic stroke (intracerebral haemorrhage (ICH) and subarachnoid haemorrhage (SAH)) outcomes.…”

Section: Introductionmentioning

confidence: 99%

Poor haemorrhagic stroke outcomes during the COVID-19 pandemic are driven by socioeconomic disparities: analysis of nationally representative data

Bako,

Potter,

Pan

et al. 2024

BMJ Neurol Open

View full text Add to dashboard Cite

BackgroundNationally representative studies evaluating the impact of the COVID-19 pandemic on haemorrhagic stroke outcomes are lacking.MethodsIn this pooled cross-sectional analysis, we identified adults (≥18 years) with primary intracerebral haemorrhage (ICH) or subarachnoid haemorrhage (SAH) from the National Inpatient Sample (2016–2020). We evaluated differences in rates of in-hospital outcomes between the prepandemic (January 2016–February 2020) and pandemic (March–December 2020) periods using segmented logistic regression models. We used multivariable logistic regression to evaluate differences in mortality between patients admitted from April to December 2020, with and without COVID-19, and those admitted from April to December 2019. Stratified analyses were conducted among patients residing in low-income and high-income zip codes, as well as among patients with extreme loss of function (E-LoF) and those with minor to major loss of function (MM-LoF).ResultsOverall, 309 965 patients with ICH (47% female, 56% low income) and 112 210 patients with SAH (62% female, 55% low income) were analysed. Prepandemic, ICH mortality decreased by ~1% per month (adjusted OR, 95% CI: 0.99 (0.99 to 1.00); p<0.001). However, during the pandemic, the overall ICH mortality rate increased, relative to prepandemic, by ~2% per month (1.02 (1.00 to 1.04), p<0.05) and ~4% per month (1.04 (1.01 to 1.07), p<0.001) among low-income patients. There was no significant change in trend among high-income patients with ICH (1.00 (0.97 to 1.03)). Patients with comorbid COVID-19 in 2020 had higher odds of mortality (versus 2019 cohort) only among patients with MM-LoF (ICH, 2.15 (1.12 to 4.16), and SAH, 5.77 (1.57 to 21.17)), but not among patients with E-LoF.ConclusionSustained efforts are needed to address socioeconomic disparities in healthcare access, quality and outcomes during public health emergencies.

show abstract

Cardiovascular disease and COVID-19, a deadly combination: A review about direct and indirect impact of a pandemic

Cited by 18 publications

References 108 publications

Toxicity Risk Assessment Due to Particulate Matter Pollution from Regional Health Data: Case Study from Central Romania

Toxicity Risk Assessment Due to Particulate Matter Pollution from Regional Health Data: Case Study from Central Romania

Aterosclerosis, Cardiovascular Disorders And Covid-19: Comorbid Pathogenesis

Poor haemorrhagic stroke outcomes during the COVID-19 pandemic are driven by socioeconomic disparities: analysis of nationally representative data

Contact Info

Product

Resources

About